The meaning of p16 ink4a expression in tumors

Functional significance, clinical associations and future developments

Agnieszka K. Witkiewicz, Karen E. Knudsen, Adam P. Dicker, Erik S. Knudsen

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

The CDKN2A gene is a tumor suppressor that encodes the CDK4/6 inhibitor p16 ink4a. Loss of this tumor suppressor contributes to the bypass of critical senescent signals and is associated with progression to malignant disease. However, the high-level expression of p16 ink4a in tumors is associated with aggressive subtypes of disease, and in certain clinical settings elevated p16 ink4a expression is an important determinant for disease prognosis and therapeutic response. These seemingly contradictory facets of p16 ink4a expression have lead to confusion related to the meaning of this tumor suppression in tumor pathobiology. As reviewed here, the alternative expression of p16 ink4a represents an ideal marker for considering RB-pathway function, tumor heterogeneity and novel means for directing therapy.

Original languageEnglish (US)
Pages (from-to)2497-2503
Number of pages7
JournalCell Cycle
Volume10
Issue number15
DOIs
StatePublished - Aug 1 2011

Fingerprint

Neoplasms
p16 Genes
Therapeutics

Keywords

  • CDK
  • CDKN2a
  • Cyclin
  • E2F
  • p16
  • Radiation
  • RB
  • Therapy

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology

Cite this

The meaning of p16 ink4a expression in tumors : Functional significance, clinical associations and future developments. / Witkiewicz, Agnieszka K.; Knudsen, Karen E.; Dicker, Adam P.; Knudsen, Erik S.

In: Cell Cycle, Vol. 10, No. 15, 01.08.2011, p. 2497-2503.

Research output: Contribution to journalArticle

Witkiewicz, Agnieszka K. ; Knudsen, Karen E. ; Dicker, Adam P. ; Knudsen, Erik S. / The meaning of p16 ink4a expression in tumors : Functional significance, clinical associations and future developments. In: Cell Cycle. 2011 ; Vol. 10, No. 15. pp. 2497-2503.
@article{2e57c8b6338c41cfb54ebd4754fd7ed6,
title = "The meaning of p16 ink4a expression in tumors: Functional significance, clinical associations and future developments",
abstract = "The CDKN2A gene is a tumor suppressor that encodes the CDK4/6 inhibitor p16 ink4a. Loss of this tumor suppressor contributes to the bypass of critical senescent signals and is associated with progression to malignant disease. However, the high-level expression of p16 ink4a in tumors is associated with aggressive subtypes of disease, and in certain clinical settings elevated p16 ink4a expression is an important determinant for disease prognosis and therapeutic response. These seemingly contradictory facets of p16 ink4a expression have lead to confusion related to the meaning of this tumor suppression in tumor pathobiology. As reviewed here, the alternative expression of p16 ink4a represents an ideal marker for considering RB-pathway function, tumor heterogeneity and novel means for directing therapy.",
keywords = "CDK, CDKN2a, Cyclin, E2F, p16, Radiation, RB, Therapy",
author = "Witkiewicz, {Agnieszka K.} and Knudsen, {Karen E.} and Dicker, {Adam P.} and Knudsen, {Erik S.}",
year = "2011",
month = "8",
day = "1",
doi = "10.4161/cc.10.15.16776",
language = "English (US)",
volume = "10",
pages = "2497--2503",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "15",

}

TY - JOUR

T1 - The meaning of p16 ink4a expression in tumors

T2 - Functional significance, clinical associations and future developments

AU - Witkiewicz, Agnieszka K.

AU - Knudsen, Karen E.

AU - Dicker, Adam P.

AU - Knudsen, Erik S.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - The CDKN2A gene is a tumor suppressor that encodes the CDK4/6 inhibitor p16 ink4a. Loss of this tumor suppressor contributes to the bypass of critical senescent signals and is associated with progression to malignant disease. However, the high-level expression of p16 ink4a in tumors is associated with aggressive subtypes of disease, and in certain clinical settings elevated p16 ink4a expression is an important determinant for disease prognosis and therapeutic response. These seemingly contradictory facets of p16 ink4a expression have lead to confusion related to the meaning of this tumor suppression in tumor pathobiology. As reviewed here, the alternative expression of p16 ink4a represents an ideal marker for considering RB-pathway function, tumor heterogeneity and novel means for directing therapy.

AB - The CDKN2A gene is a tumor suppressor that encodes the CDK4/6 inhibitor p16 ink4a. Loss of this tumor suppressor contributes to the bypass of critical senescent signals and is associated with progression to malignant disease. However, the high-level expression of p16 ink4a in tumors is associated with aggressive subtypes of disease, and in certain clinical settings elevated p16 ink4a expression is an important determinant for disease prognosis and therapeutic response. These seemingly contradictory facets of p16 ink4a expression have lead to confusion related to the meaning of this tumor suppression in tumor pathobiology. As reviewed here, the alternative expression of p16 ink4a represents an ideal marker for considering RB-pathway function, tumor heterogeneity and novel means for directing therapy.

KW - CDK

KW - CDKN2a

KW - Cyclin

KW - E2F

KW - p16

KW - Radiation

KW - RB

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=79961117100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961117100&partnerID=8YFLogxK

U2 - 10.4161/cc.10.15.16776

DO - 10.4161/cc.10.15.16776

M3 - Article

VL - 10

SP - 2497

EP - 2503

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 15

ER -